NCT05946564 A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
| NCT ID | NCT05946564 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | ANCA Associated Vasculitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2023-10-24 |
| Primary Completion | 2028-04-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 126 participants in total. It began in 2023-10-24 with a primary completion date of 2028-04-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The RENATO trial is a multicenter randomized controlled trial that evaluates the efficacy of pioglitazone to improve renal outcomes in ANCA-associated vasculitis. Patients with biopsy-proven kidney involvement of ANCA vasculitis will be included in this trial at diagnosis. All patients will receive a standard of care immunosuppressive (SOC) therapy combining corticosteroids and rituximab (375 mg/m2/week for 4 consecutive weals followed by 500 mg re-infusion every 6 months). They will be randomized 1:1 to receive either pioglitazone 30 mg/day or placebo for 6 months, on top of SOC. The primary objective of this trial is to demonstrate that pioglitazone reduces kidney damage, reflected by the early improvement of proteinuria and serum creatinine levels. The secondary objectives will be to assess the efficacy of this drug on the reduction of hypertension and metabolic effects of glucocorticoids, to measure its impact on vasculitis activity and to evaluate the safety profile of pioglitazone in this population.
Eligibility Criteria
Inclusion Criteria: * Newly-diagnosed or relapsing ANCA-associated vasculitis, i.e. granulomatosis with polyangitis (GPA) or microscopic polyangiitis (MPA), according to ACR 1990 criteria and/or revised Chapel Hill Consensus Conference definitions and/or European Medical Agency algorithm, with an active disease defined as a BVAS ≥3 * Presence of proteinuria (UPCR \>300 mg/g), haematuria (\>10 RBC/hpf), and eGFR ≥15 mL/min/1.73 m2 (CKD-EPI formula) at inclusion (\<1 month) * Recent (\<4 weeks) renal biopsy that confirms active renal involvement of ANCA-associated vasculitis * Patients aged of 18 to 80 years * Participant written informed consent prior to participation in the study * Participants affiliated to a French health insurance system (registered or being a beneficiary of such a scheme) Exclusion Criteria: * Alveolar haemorrhage requiring pulmonary ventilation support at inclusion * Patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) * Active cancer (except non-melanoma skin cancer) within the past 24 months * Active severe bacterial, viral or fungal infectious disease * Past history of bladder or urinary tract cancer * History of Class 3/4 congestive heart failure symptoms, any time * History of Class 2 heart failure symptoms within the past 3 months and/or ejection fraction \<40% on recent echocardiography (\<1 month) * Transaminases levels above 2 times the normal range value (\<1 month) or any severe chronic liver disease * Positive serology for HIV, HBV (Ag HBs positivity) or active HCV infection at inclusion * Presence of neutropenia \<1000 cells/l (\<1 month) * History of intolerance to any thiazolidinedione (including Pioglitazone), to rituximab or any excipient listed in SmPc * Diabetic ketoacidosis, any time * A pre-existing or an important risk of new-onset macular edema (confirmed by an ophthalmological examination) * Pregnant or breast-feeding women, or desire to become pregnant within 24 months All women of childbearing potential (WOCBP) are required to have a negative pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using an effective method of birth control from the date of consent through the end of the study and another 12 months after (or 12 months after the last rituximab infusion in case of premature termination): Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner * Severe neurologic or psychiatric disease (e.g., dementia or schizophrenia) * Kidney transplant recipients * Cyclophosphamide or rituximab (dose \> 375 mg/m2) use within 26 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the first rituximab dose. Patients that have initiated induction therapy with rituximab for the actual flare, can be included in the present study within 48h following the first rituximab infusion * Intravenous glucocorticoids, \>3000 mg methylprednisolone equivalent, within 4 weeks prior to screening * Patients who have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening * Current participation in another research study involving a therapeutic intervention. Participation to an observational research, or a non-interventional research is allowed * Patients under guardianship or curators and protected adults * Patients not able to understand and follow study procedures * Patients on AME (Aide Médicale de l'Etat = State Medical Assistance)
Contact & Investigator
Alexandre Karras
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05946564 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying ANCA Associated Vasculitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05946564 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 126 participants.
Is NCT05946564 currently recruiting?
Yes, NCT05946564 is actively recruiting participants. Contact the research team at maxime.brussieux@aphp.fr for enrollment information.
Where is the NCT05946564 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Boulogne-sur-Mer, France, Brest, France and 11 additional locations.
Who is sponsoring the NCT05946564 clinical trial?
NCT05946564 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Alexandre Karras at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 126 participants.